Medications initially developed for managing diabetes and obesity are broadening their therapeutic applications. Recently, treatments based on the hormone GLP-1 have demonstrated benefits not only in weight loss and improved glycemic control but also in various health issues, including cardiovascular diseases, kidney complications, and polycystic ovary syndrome. Researchers are now exploring an intriguing possibility: these medications may also help mitigate cravings for substances like alcohol, tobacco, and narcotics.

Recent Findings from a Large US Study

A substantial study conducted in the United States, published in a medical journal, indicates that GLP-1 receptor agonists may lower the likelihood of developing substance use disorders across multiple categories. These substances include alcohol, cannabis, cocaine, nicotine, and opioids. The analysis concluded that the use of these medications was consistently linked to a reduced risk of new substance use disorders, implying a broad preventive effect across various substances. Additionally, among individuals already facing substance use issues, the use of GLP-1 receptor agonists correlated with fewer adverse clinical outcomes.

Mechanism of Action of GLP-1 Based Drugs

GLP-1 based medications work by mimicking natural gut hormones that regulate appetite, insulin secretion, and digestion. Over the last decade, they have gained significant popularity as effective treatments for weight management and diabetes. Commonly known drugs in this category, such as Ozempic, Wegovy, and Mounjaro, are now in demand due to their remarkable impact on weight loss and metabolic health. India witnessed the introduction of these injectable drugs last year, quickly gaining traction among patients and healthcare providers. Researchers are particularly interested in how these therapies affect the brain’s reward systems, which may explain their impact on cravings for alcohol and other substances.

Details of the Research Analysis

The recent findings were derived from an analysis involving over 600,000 US veterans diagnosed with type 2 diabetes, monitored for a span of three years. Participants were categorized into two groups: one receiving GLP-1 receptor agonists and the other treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors, another category of diabetes medications. Among veterans without prior substance use history, those starting on GLP-1 receptor agonists exhibited a 14 percent reduction in the overall risk of developing substance use disorders compared to those on SGLT-2 inhibitors. Notable risk reductions were observed for specific substances as well; alcohol use disorder dropped by 18 percent, cannabis by 14 percent, cocaine by 20 percent, nicotine by 20 percent, and opioid use disorder by 25 percent. In tangible terms, this represented approximately one to six fewer cases per 1,000 individuals over three years.

Insights from Healthcare Professionals

Dr. Anoop Misra, a prominent clinician and researcher, suggested that the results may be linked to how these medications interact with the brain’s reward mechanisms. According to Dr. Misra, the drugs affect the mesolimbic reward pathways, which are crucial for processing pleasure. Furthermore, they have shown potential in curbing cravings for unhealthy foods and other recreational substances. Dr. Rajeev Jayadevan, a gastroenterologist, has pointed out that anecdotal evidence from patients indicates a decline in cravings for alcohol and tobacco among those receiving GLP-1 injections for weight management.

Behavioral Influences and Small-Scale Studies

One possible explanation for these findings could be behavioral. Patients undergoing treatment with these medications are often encouraged to adopt healthier lifestyle changes, potentially motivating them to reduce alcohol consumption or smoking. This hypothesis has been tested in a small randomized controlled trial involving 48 individuals with alcohol use disorder, where participants displayed a significant decrease in the total alcohol consumed on drinking days despite no reduction in the number of drinking days. Critics of the study noted that its small size and the possibility of participants recognizing they were receiving the treatment could influence behavior, leaving open questions regarding the validity of these effects.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share